CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Pazopanibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01253369
NCT01253369Phase 2Completed
CompareCT.gov

A Phase II Study of Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC)

Dana-Farber Cancer Institute·interventional·Posted Dec 3, 2010·Updated Apr 23, 2019

In Brief

A Phase 2 clinical trial evaluating Pazopanib for Small Cell Lung Cancer and 2 related conditions. Completed, enrolled 33 participants across 3 sites.

Detailed Summary

Pazopanib is a drug that inhibits proteins thought to be important for new blood vessel formation. This drug has been used in other cancer research studies and information from those studies suggests that pazopanib may help block proteins that are important for the growth, invasion, and spread of cancer cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer, Lung Cancer, SCLC
CountriesUnited States
CollaboratorsMassachusetts General Hospital, Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, GlaxoSmithKline

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 3, 2010
Enrollment StartJun 1, 2010
Primary CompletionSep 1, 2012
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.6 years ago

Interventions

Pazopanibdrug